The additional benefit observed with anti-CTLA-4 in subcutaneous tumours may reflect depletion of T regulatory cells (Tregs) or attenuation of CTLA-4-mediated inhibition of positive co-stimulation of effector T cells by CD2835. Here, CTLA4 is linked to neoplasm.